RPRiccardo Patacchini

Riccardo Patacchini

*This is an algorithmically generated author record based on publicly available information.

Riccardo Patacchini has a total of 32 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • α,β-Unsaturated aldehydes contained in cigarette smoke elicit IL-8 release in pulmonary cells through mitogen-activated protein kinases

    by Nadia Moretto, Fabrizio Facchinetti, Thomas Southworth, Maurizio Civelli, Dave Singh, Riccardo Patacchini

    Cigarette smoking is the major risk factor for chronic obstructive pulmonary disease (COPD), a syndrome characterized by pulmonary neutrophil infiltration, chronic inflammation, and progressive tissue destruction. We examined here the acute effect of aqueous cigarette smoke extract (CSE) and of two α,β-unsaturated aldehydes (acrolein and crotonaldehyde) contained in CSE in cultured normal human lung fibroblasts and small airway epithelial cells. By examining a panel of 19 cytokines and chemokines, we found that IL-8 release was elevated by CSE as well as by acrolein, whereas other inflammatory mediators were mostly unaffected. CSE-evoked IL-8 release was mimicked by acrolein and crotonaldehyde at concentrations (3–60 μM each) found in CSE and fully prevented by 1 mM α,β-unsaturated aldehydes scavengers N-acetylcysteine (NAC) or sodium 2-mercaptoethanesulfonate. Neither the saturated aldehyde acetaldehyde nor H2O2evoked IL-8 release. In addition, CSE or crotonaldehyde upregulated the release of IL-8 from alveolar macrophages from both COPD patients and healthy nonsmokers, indicating that this is a response common to cells involved in lung inflammation. CSE-evoked IL-8 release was accompanied by increased phosphorylation of p38 MAPK and ERK1/2. CSE-evoked p38 and ERK1/2 phosphorylation was mimicked by acrolein and inhibited by NAC. IL-8 release elicited by both acrolein and CSE was blocked by pharmacological inhibition of p38 and ERK1/2 phosphorylation. In summary, our data show that α,β-unsaturated aldehydes-evoked phosphorylation of p38 and ERK1/2 underlies IL-8 release elicited by CSE, thus shedding light on the mechanisms through which cigarette smoke can initiate inflammation in the lung.


  • T1439 Reactive Prostaglandins (PG) Activate Transient Receptor Potential (TRP) A1 On Nociceptive Neurons to Induce Pain

    by Eunice Andre, Serena Materazzi, Romina Nassini, Silvia Amadesi, Riccardo Patacchini, Pierangelo Geppetti, Nigel W. Bunnett

  • α,β-Unsaturated Aldehydes in Cigarette Smoke Release Inflammatory Mediators from Human Macrophages

    by Fabrizio Facchinetti, Francesco Amadei, Pierangelo Geppetti, Francesca Tarantini, Claudia Di Serio, Alberto Dragotto, Paolo M. Gigli, Silvia Catinella, Maurizio Civelli, Riccardo Patacchini

    Smoking cigarettes is the major risk factor for chronic obstructive pulmonary disease (COPD). COPD is a condition associated with chronic pulmonary inflammation, characterized by macrophage activation, neutrophil recruitment, and cell injury. Many substances contained in cigarette smoke, including reactive oxygen species (ROS), have been proposed to be responsible for the inflammatory process of COPD. However, this issue remains unsettled. By gas chromatography/mass spectrometry (GC/MS) we show that acrolein and crotonaldehyde, two α,β-unsaturated aldehydes, are contained in aqueous cigarette smoke extract (CSE) at micromolar concentrations and mimic CSE in evoking the release of the neutrophil chemoattractant IL-8 and of the pleiotropic inflammatory cytokine TNF-α from the human macrophagic cell line U937. In addition, acrolein (10–30 μM) released IL-8 also from cultured human alveolar macrophages and THP-1 macrophagic cells. 4-hydroxy-2-nonenal (30–100 μM), an endogenous α,β-unsaturated aldehyde that is...


  • Pharmacological assessment of the duration of action of glycopyrrolate vs tiotropium and ipratropium in guinea‐pig and human airways

    by Gino Villetti, Marco Bergamaschi, Franco Bassani, Pier Tonino Bolzoni, Selena Harrison, Paolo M Gigli, Alberto Janni, Pierangelo Geppetti, Maurizio Civelli, Riccardo Patacchini

    Our study was aimed at investigating the duration of the bronchodilator action of the antimuscarinc drug glycopyrrolate compared to tiotropium and ipratropium. In the guinea‐pig isolated trachea, the time (t1/2) necessary for a contractile response to carbachol (0.3 μM) to return to 50% recovery after washout of the antagonist was studied. The offset of the antagonist effect of glycopyrrolate, tiotropium and ipratropium (10 nM each) was t1/2=4.0±0.5, >4.5 and 0.5±0.1 h, respectively. At 4.5 h from the washout of the antagonist, the recovery of the response to carbachol was 50±8, 10±4 and 70±7%, respectively. In the human isolated bronchus, the offset of the bronchodilator effects of glycopyrrolate (3 nM), tiotropium (1 nM) and ipratropium (10 nM) was t1/2=3.7±0.2; >6 and 3.0±0.2 h, respectively. At 6.0 h from the washout of the antagonist, the recovery of the response to carbachol (1 μM) was 101±10, 27±3 and 110±10%, respectively. In anaesthetized guinea‐pigs, acetylcholine‐induced bronchoconstriction was markedly reduced by intratracheal instillation of glycopyrrolate (3 nmol kg−1; 88.1±4% inhibition), tiotropium (1.3 nmol kg−1; 86.2±5% inhibition) or ipratropium (1.45 nmol kg−1; 88.1±10% inhibition). These inhibitory effects assessed 3 or 24 h after antagonist administration were reduced to 69.9±5 and 29.7±6%; 28.3±5 and 14.2±5% for glycopyrrolate and ipratropium, respectively, whereas they remained stable (83.5±4; 70.6±6) for tiotropium. The residual inhibitory effect of glycopyrrolate was also assessed at 16 h from administration, and proved to be as low as that found at 24 h (31.2±10 vs 29.7±6%, respectively). In conclusion, glycopyrrolate‐induced bronchodilation has a longer duration than that of ipratropium, but less than that of tiotropium. The efficacy of a possible glycopyrrolate‐based therapy for asthma or chronic obstructive pulmonary disease given once‐a‐day is not guaranteed by the present investigation. British Journal of Pharmacology (2006) 148, 291–298. doi:10.1038/sj.bjp.0706724


  • Pharmacological investigation of hydrogen sulfide (H2S) contractile activity in rat detrusor muscle

    by Riccardo Patacchini, Paolo Santicioli, Sandro Giuliani, Carlo Alberto Maggi


  • Open Access

    Further evidence for the existence of NK2 tachykinin receptor subtypes

    by Riccardo Patacchini, Mara Astolfi, Laura Quartara, Paolo Rovero, Antonio Giachetti, Carlo Alberto Maggi

    1 We have evaluated the biological activity of a number of neurokinin A (4–10), (NKA (4–10)) analogues in the endothelium-deprived rabbit isolated pulmonary artery (RPA) and hamster isolated trachea (HT), two tissues rich in different NK2 receptor subtypes. 2 MDL 28,564, a pseudopeptide selective for NK2 receptor sites, behaved as a full agonist in the RPA, while in the HT it competitively antagonized NKA or [βAla8]-NKA (4–10) contractile effects. 3 The peculiar behaviour of MDL 28,564 in the RPA and HT may be explained neither by a difference in receptor reserve between the two organs (the reserve being three times greater in RPA than in the HT) nor by a different affinity for the two receptor subtypes (identical dissociation constants, pKA or pKB, calculated in the RPA and in the HT). On the other hand, MDL 28,564 displayed a very different intrinsic efficacy for the two receptor subtypes. 4 The novel peptides MEN 10,295 ([Trp7, βAla8]-NKA-(4–10)) and MEN 10,296 ([Tyr5, Trp7, βAla8]-NKA-(4–10)) behaved as weaker agonists than MDL 28,564 in the RPA, but retained appreciable agonist activity also in the HT. 5 The novel peptides: MEN 10,282 ([Tyr5, d-Trp6,8, Trp9, Arg10]-NKA-(4–10)), MEN 10,449 ([diI-Try5, d-Trp6,8,9, Arg10]-NKA-(4–10)) and the cyclic hexapeptide L 659,877 (cyclo [Leu-Met-Gln-Trp-Phe-Gly]) behaved as competitive antagonists against NKA contractile effects both in the RPA and HT. MEN 10,282 and MEN 10,449 were unable to distinguish between the NK2 receptor subtypes, having almost the same affinity in the two organs. On the other hand L 659,877 was about 15 times more potent in the HT than in the RPA. 6 These results provide further evidence for NK2 receptors heterogeneity and are useful in outlining pharmacological features of the two subtypes present in the RPA and HT.